Academic Journals Database
Disseminating quality controlled scientific knowledge

Eribulin mesylate in the treatment of metastatic breast cancer

ADD TO MY LIST
 
Author(s): Jain S | Cigler T

Journal: Biologics : Targets & Therapy
ISSN 1177-5475

Volume: 2012;
Issue: default;
Start page: 21;
Date: 2012;
Original page

ABSTRACT
Sarika Jain, Tessa CiglerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAAbstract: The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.Keywords: eribulin, metastatic breast cancer, microtubule
Affiliate Program      Why do you need a reservation system?